Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Dermatologic 2Breast 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 22Melanoma 8Triple Negative Breast Neoplasms 7Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Colorectal Neoplasms 6Uterine Cervical Neoplasms 3Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Breast Neoplasms, Male 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Skin Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Transitional Cell 2Uveal Melanoma 1Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Recurrence 1Rectal Neoplasms 1

Interventions

pembrolizumab 14Docetaxel 7cemiplimab 4avelumab 4Trastuzumab 4Paclitaxel 4fludarabine 3durvalumab 3atezolizumab 3Psychiatric Rehabilitation 3Nivolumab 3Methods 3Gemcitabine 3Fluorouracil 3Early Intervention, Educational 3Cyclophosphamide 3Carboplatin 3Biopsy 3zimberelimab 2poly ICLC 2palbociclib 2belinostat 2amminedichloro(2-methylpyridine)platinum(II) 2Tetrahydrouridine 2Taxes 2Standard of Care 2Specimen Handling 2Sirolimus 2Radiotherapy 2Positron-Emission Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Interleukin-2 × Breast × Clear all
NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 14 charts
BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡